- Motley Fool•2 days ago
Teva's oncology division could be on the chopping block.
- Reuters•2 days ago
Canadian drugmaker Valeant Pharmaceuticals International Inc said it had priced its recently approved plaque psoriasis treatment at $3,500 per month, ahead of an expected U.S. launch in the second half of 2017. Siliq is the lowest priced injectable biologic psoriasis treatment currently on the market, Valeant said on Friday. The treatment, which blocks a cell receptor known as interleukin-17 to tamp down inflammation, will compete with a host of existing IL-17 inhibitors including Cosentyx from Novartis AG and Taltz from Eli Lilly & Co.
- The Wall Street Journal•4 days ago
By putting some of their wealth in private ‘family offices’ and other personal investment vehicles, some billionaire managers of private-equity and hedge funds are dividing their time, duplicating strategies ...
BVF.BE : Summary for VALEANT PHARMACEUT. INTL - Yahoo Finance
VALEANT PHARMACEUT. INTL (BVF.BE)
Berlin - Berlin Delayed Price. Currency in EUR
Add to watchlist
|Day's Range||8.58 - 8.58|
|52 Week Range||7.76 - 16.70|
|PE Ratio (TTM)||N/A|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|